High And Intermediate-High Risk Pulmonary Embolism Management: A 5-Year Intensive Care Unit Casuistic Review
DOI:
https://doi.org/10.48729/pjctvs.415Keywords:
acute pulmonary embolism, pulmonary embolism response team, systemic thrombolysis, Extracorporeal Membrane Oxygenation, chronic thromboembolic pulmonary hypertensionAbstract
Background and Objectives: The optimal management of high-risk and intermediate-high-risk Pulmonary Embolism (PE) is a matter of ongoing debate. This paper aims to assess the short and long-term clinical outcomes associated with different treatment approaches for high-risk and intermediate-high-risk PE within an Intensive Care Unit (ICU) and identify potential areas for improvement.Methods: We conducted a retrospective analysis of patients admitted to an ICU with high and intermediate-high-risk PE between January 2018 and December 2023. The therapeutic approach and clinical outcomes were evaluated: ICU and 28-days survival, ICU and hospital length of stay, major hemorrhagic complications and direct and indirect signs of pulmonary hypertension (PHT). Demographic, comorbid state and severity at admission data were also collected (sex, age, Charlson Comorbidity and APACHE II scores).
Results: 64 patients were included: 32 high-risk PE (including 18 in cardiac arrest) [Groups 1-5] and 32 intermediate-high-risk PE [Group 6a-c]. Treatment approaches varied: Group 1 - High-risk PE treated with systemic thrombolysis (ST) (n=18); Group 2 - High-risk PE treated with Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) plus ST (n=6); Group 3 - High-risk PE treated with VA-ECMO alone (n=5); Group 4 - High-risk PE treated with catheter-direct-therapy (n=1); Group 5 - Heparin only (n=2). Group 1 demonstrated an ICU and 28-day survival of 83.0%, while Groups 2 and 3 exhibited survival rates of 66.67% and 60.0%, respectively. There were 10 major bleeding complications in Group 1 and 2. For intermediate-high-risk PE, heparin alone was used in 90%; ICU and 28-day survival rate was 97%. Three patients exhibited signs of PHT during follow-up.
Conclusion: This paper provides insights for the decision-making process involved in managing high and intermedi- ate-high-risk PE drawing from a 5-year retrospective cohort study conducted at an ECMO center and literature review. Fur- ther research is needed to identify the specific subgroup within the intermediate-high-risk PE that would benefit from more advanced treatment modalities for both short and long-term outcomes.
Downloads
References
Martinez Licha, C.R., et al., Current Management of Acute Pulmonary Embolism. Annals of Thoracic and Cardiovascular Surgery, 2020. 26(2): p. 65-71.
Rivera-Lebron, B., et al., Diagnosis, Treatment and Follow Up of Acute Pulmonary Embolism: Consensus Practice from the PERT Consortium. Clinical and Applied Thrombosis/Hemostasis, 2019. 25: p. 1076029619853037.
Weinstein, T., H. Deshwal, and S.B. Brosnahan, Advanced management of intermediate-high risk pulmonary embolism. Critical Care, 2021. 25(1): p. 311.
Assouline, B., et al., Management of High-Risk Pulmonary Embolism: What Is the Place of Extracorporeal Membrane Oxygenation? Journal of Clinical Medicine, 2022. 11(16): p. 4734.
Konstantinides, S.V., et al., 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). European Heart Journal, 2019. 41(4): p. 543-603.
Tapson, V.F. and A.S. Weinberg, Overview of Management of Intermediate- and High-Risk Pulmonary Embolism. Critical Care Clinics, 2020. 36(3): p. 449-463.
Liang, Y., et al., Role of Pulmonary Embolism Response Team in patients with intermediate- and high-risk pulmonary embolism: a concise review and preliminary experience from China. J Geriatr Cardiol, 2020. 17(8): p. 510-518.
Sosa, D.F., et al., Impact of pulmonary embolism response teams on acute pulmonary embolism: a systematic review and meta-analysis. European Respiratory Review, 2022. 31(165): p. 220023.
Giri, J., et al., Interventional Therapies for Acute Pulmonary Embolism: Current Status and Principles for the Development of Novel Evidence: A Scientific Statement From the American Heart Association. Circulation, 2019. 140(20): p. e774-e801.
Keller, K., et al., Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. European Heart Journal, 2019. 41(4): p. 522-529.
Hobohm, L., et al., Clinical use and outcome of extracorporeal membrane oxygenation in patients with pulmonary embolism. Resuscitation, 2022. 170: p. 285-292.
Theroux, C.D., J.M. Aliotta, and C.J. Mullin, High-Risk Pulmonary Embolism: Current Evidence-Based Practices. R I Med J (2013), 2019. 102(10): p. 43-47.
O’Malley, T.J., et al., Outcomes of extracorporeal life support for the treatment of acute massive pulmonary embolism: A systematic review. Resuscitation.
Rivers, J., et al., Extracorporeal membrane oxygenation for the treatment of massive pulmonary embolism. An analysis of the ELSO database. Resuscitation, 2023. 191: p. 109940.
Corsi, F., et al., Life-threatening massive pulmonary embolism rescued by venoarterial-extracorporeal membrane oxygenation. Critical Care, 2017. 21(1): p. 76.
Giraud, R., et al., Can VA-ECMO Be Used as an Adequate Treatment in Massive Pulmonary Embolism? Journal of Clinical Medicine, 2021. 10(15): p. 3376.
Maggio, P., et al., Extracorporeal Life Support for Massive Pulmonary Embolism. Journal of Trauma and Acute Care Surgery, 2007. 62(3): p. 570-576.
Ius, F., et al., Extracorporeal membrane oxygenation and surgical embolectomy for high-risk pulmonary embolism. European Respiratory Journal, 2019. 53(4): p. 1801773.
Meneveau, N., et al., Outcomes after extracorporeal membrane oxygenation for the treatment of high-risk pulmonary embolism: a multicentre series of 52 cases. European Heart Journal, 2018. 39(47): p. 4196-4204.
Murguia, A.R., et al., Reduced-Dose Thrombolysis in Acute Pulmonary Embolism A Systematic Review. Angiology. 0(0): p. 00033197231167062.
Wang, C., et al., Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest, 2010. 137(2): p. 254-62.
Kiser, T.H., et al., Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. Crit Care Med, 2018. 46(10): p. 1617-1625.
Machanahalli Balakrishna, A., et al., Intermediate-Risk Pulmonary Embolism: A Review of Contemporary Diagnosis, Risk Stratification and Management. Medicina (Kaunas), 2022. 58(9).
Piazza, G., Advanced Management of Intermediate- and High-Risk Pulmonary Embolism: JACC Focus Seminar. Journal of the American College of Cardiology, 2020. 76(18): p. 2117-2127.
Meyer, G., et al., Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 2014. 370(15): p. 1402-1411.
Sanchez, O., et al., Reduced-Dose Intravenous Thrombolysis for Acute Intermediate-High-risk Pulmonary Embolism: Rationale
and Design of the Pulmonary Embolism International THrOmbolysis (PEITHO)-3 trial. Thromb Haemost, 2022. 122(5): p. 857-866.
Polen, C.B., H.N. Mullins Busch, and P.D. Ratliff, Treatment of a mobile intracardiac thrombus using ultra-slow low-dose tissue plasminogen activator in combination with heparin. J Clin Pharm Ther, 2018. 43(2): p. 284-286.
Duffett, L., L.A. Castellucci, and M.A. Forgie, Pulmonary embolism: update on management and controversies. BMJ, 2020. 370: p. m2177.
Yang, S., et al., Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. J Thorac Dis, 2015. 7(11): p. 1927-38.
Sharifi, M., et al., Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol, 2013. 111(2): p. 273-7.
Konstantinides, S.V., et al., Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. J Am Coll Cardiol, 2017. 69(12): p. 1536-1544.
Downloads
Published
How to Cite
License
Copyright (c) 2024 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
This work is licensed under a Creative Commons Attribution 4.0 International License.
